Emergent BioSolutions Inc. Overview
Pro stress-test →Emergent BioSolutions provides specialty products for civilian and military populations that address intentional and naturally emerging public health threats. The company operates through two primary segments: commercial products (including NARCAN naloxone for opioid overdose) and medical countermeasures (MCM) vaccines and treatments for biodefense and emerging infectious diseases, plus a contract development and manufacturing services (CDMO) division.
Strategic Profile
Pro stress-test →Chief Executive Officer Joe Papa highlighted substantial progress executing on the company's transformation plan over the past few years, citing operating results, strategic divestitures, margin improvements, and deleveraging through debt repayment. MCM revenue is expected to be flat to slightly down, with management citing continued strength in international demand but noting that 2025 benefited from an "exceptionally strong" $60 million international customer order that is not currently assumed to repeat in 2026.
Competitive Landscape
Pro stress-test →The company expects NARCAN to maintain its leading market share in the commercial naloxone segment. In medical countermeasures, Emergent competes against government contracts and other specialized biodefense companies. The CDMO segment serves a fragmented market of pharma and biotech clients.
Industry Context
Emergent BioSolutions Inc. operates in Specialty Biopharmaceuticals & Medical Countermeasures / Contract Manufacturing.
Key facts
Founded: 1998 · Headquarters: Gaithersburg, Maryland · Revenue: $789M (TTM) · Market cap: $430M